GlassScriptPhysician profile
Justin Pandoo
NPI 1659755361
$5,199.97
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $1,364 · 2021: $1,285 · 2022: $1,458 · 2023: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $447.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $614.26 | 2020-2023 | Mounjaro, Trulicity, Jardiance |
| Novo Nordisk INC | $468.80 | 2019-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $452.58 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $449.03 | 2019-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $320.78 | 2022-2023 | |
| Glaxosmithkline, LLC. | $307.12 | 2019-2023 | Trelegy Ellipta |
| Amarin Pharma, INC. | $287.37 | 2020-2021 | |
| Allergan, INC. | $276.50 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $272.82 | 2019-2022 | |
| Pfizer INC. | $198.39 | 2019-2023 | |
| Currax Pharmaceuticals LLC | $193.10 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $190.28 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $147.14 | 2022-2023 | Quviviq |
| Amgen INC. | $131.83 | 2019-2023 | Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.96 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $108.56 | 2019-2021 | |
| Eisai INC. | $101.17 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $91.67 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.92 | 2019-2021 | |
| Abbott Laboratories | $51.55 | 2022 | |
| Janssen Pharmaceuticals, INC | $51.02 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.38 | 2022 | |
| Dexcom, INC. | $30.32 | 2021-2022 | |
| Astellas Pharma US INC | $30.27 | 2021 | |
| Merck Sharp & Dohme LLC | $29.34 | 2020 | |
| Genentech USA, INC. | $27.48 | 2019-2020 | |
| Medicure Pharma INC. | $24.15 | 2021 | |
| Vanda Pharmaceuticals INC. | $23.48 | 2020 | |
| Mylan Specialty L.P. | $23.08 | 2023 | Yupelri |
| Shire North American Group INC | $22.10 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.72 | 2021 | |
| Clarus Therapeutics INC. | $16.34 | 2021 | |
| Horizon Therapeutics Plc | $14.20 | 2021 | |
| Optinose US, INC. | $13.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Pandoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.